Glow-in-the-Dark dye could reveal immune activity in Alzheimer's brains

NCT ID NCT05482867

Completed Knowledge-focused Sponsor: MindImmune Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study explores whether a dye called indocyanine green (ICG) can be used to track immune cells in the brain of people with Alzheimer's. Participants receive an ICG infusion, and a special light device measures the dye in the brain after 48 hours. The goal is to develop a non-invasive method to study immune cell activity, which may help understand Alzheimer's better. The trial includes both healthy volunteers and people with probable Alzheimer's.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: indocyanine green (ICG)
What this could lead to: If successful, this method could help researchers see how immune cells behave in Alzheimer's, potentially leading to earlier detection or new treatments.
What could go wrong: This is an early, small study focused on developing a technique, not treating the disease. The method may not work as hoped or may not be useful in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates